Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis
Cancer Treatment Reviews, 08/16/2012
Evidence Based Medicine
Peddi P et al. – Denosumab was more effective than zoledronic acid in reducing the incidence of skeletal–related events (SRE), and delayed the time to SRE. No differences were found between denosumab and zoledronic acid in reducing overall mortality, or in the frequency of overall adverse events.